Northwest Biotherapeutics (NWBO) 13F Holdings Overview (Q2 2026)

NWBO ranks #10294 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

9 institutions disclose a position in NWBO, but none treat it as a major bet — even Compass Financial Management LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Opus Capital Group, LLC has trimmed its NWBO position for two straight quarters, cutting it by $14.0K while still holding $11.0.

NWBO reported a net loss of $37.7M over the trailing twelve months.

• Not yet profitable — net loss of $37.7M over the trailing twelve months
• Revenue grew 98.6% year over year
• Net income improved year over year, from -$82.3M to -$37.7M
• Operating cash flow was negative, using $44.8M in cash
• Current ratio of 0.06x — below the conventional 1.5x liquidity buffer